$ADXS - Advaxis Immunotherapies DD Thread π₯
Produced by - @MrMikeInvesting
Company Overview
β’ Advaxis Inc engages in the discovery,development, commercialization of cancer immunotherapies
β’ Advaxis has 145M shares Outstanding and 140M of them are public float
β’This company was founded on 2002 in NJ and its HQ is located in Princeton,NJ
Page 1
Clinical Pipeline
-ADXS-HOT: Off-the-shelf, tumor type-specific constructs
-ADXS-503 in NSCLC in Phase 1/2 study
-ADXS-504 in prostate cancer scheduled,enter clinic in Q3 2021
-ADXS-HPV HPV+cancers
Upcoming Milestones
ADXS-504: Clinical trial initiation + data readout
Page 2
Merger Agreements
β’ Advaxis has Entered into a merger agreement with Biosight
β’ The combined company is expected to have approximately $50M from the merger in Q4 2021
β’ Advaxis will be renamed Biosight Therapeutics and will trade on the Nasdaq, ticker symbol BSTX
Page 3
Advaxis Experienced Management
Kenneth A. Berlin/CEO
Worked at: Veridex,J&J,Rosetta Genomics,Ortha Clinical
Dr. Robert Petit
Worked at: Biomarin,Proteolix,Sunesis,Bristol Myers,Ncolytics,Mellas
Dr. Andres Gutierrez/CMO
Worked at: Aesgen, MGI, Pharmacia, Bristol Myers
Page 4
Advaxis has a total of 57 institutional owners,56 long,1 short
Institutions own 7% of the total shares which= $10M
β’ Many major institutions are invested into Advaxis
β’ Some include:
β’ Morgan Stanley
β’ Blackrock
β’ Wells Fargo
β’ Bank of America
fintel.io/so/us/adxs
Page 5
Insider Ownership
β’ Advaxis has a total of 21 insider Owners
β’ Insider own .42% of the total shares and this equates to 605,614 shares
β’ As the merger comes closer insider trading should significantly ramp up
Page 6
I would like to now conclude this DD Thread on Advaxis Immunotherapies
Price Targets π―
Short Term ($1-$2.5)
Long Term ($4-$7)
@Ultra_Calls
@RadioSilentplay
@LadeBackk
Page 7
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.